Kangaroo
Active Member
- Messages
- 9,893
- Reaction score
- 1
http://news.yahoo.com/news?tmpl=story&cid=594&e=4&u=/nm/20050718/hl_nm/genentech_lucentis_dc
NEW YORK (Reuters) - Genentech Inc. on Monday said the average patient with age-related macular degeneration who received its experimental drug Lucentis could read an additional seven letters of a reading chart, compared with a vision loss of 10.5 letters among those who received sham injections.
The favorable difference, amounting to about 17 letters, was seen in a one year-trial, whose results were presented by researchers at a medical meeting in Montreal.
Genentech has said that U.S. regulators would likely require its drug to show a difference -- in favor of Lucentis -- of 15 letters. Each line on a reading chart consists of five letters, so a 15-letter difference is equivalent to the difference in reading three lines of a reading chart.
NEW YORK (Reuters) - Genentech Inc. on Monday said the average patient with age-related macular degeneration who received its experimental drug Lucentis could read an additional seven letters of a reading chart, compared with a vision loss of 10.5 letters among those who received sham injections.
The favorable difference, amounting to about 17 letters, was seen in a one year-trial, whose results were presented by researchers at a medical meeting in Montreal.
Genentech has said that U.S. regulators would likely require its drug to show a difference -- in favor of Lucentis -- of 15 letters. Each line on a reading chart consists of five letters, so a 15-letter difference is equivalent to the difference in reading three lines of a reading chart.